Malignant Neoplasm: Clinical Trials

109 completed, 43 recruiting, 28 terminated, 13 unknown. 85 Not applicable, 45 Phase 2, 34 Phase 1, 15 Phase 3, 9 Early Phase 1.

By phase and status

Phase	Trials	Status
Not applicable	85	Completed 50, Terminated 15, Recruiting 5, Unknown 5, Withdrawn 5, Active not recruiting 4, Suspended 1
Phase 2	45	Recruiting 19, Completed 15, Terminated 4, Active not recruiting 2, Not yet recruiting 2, Unknown 2, Withdrawn 1
Phase 1	34	Completed 16, Recruiting 11, Not yet recruiting 2, Terminated 2, Unknown 2, Active not recruiting 1
Phase 3	15	Completed 6, Recruiting 5, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1
Early Phase 1	9	Recruiting 4, Completed 2, Not yet recruiting 1, Unknown 1, Withdrawn 1

Follow Malignant Neoplasm: new trials by email Literature Review of Malignant Neoplasm trials Research Report on Malignant Neoplasm

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002) MK-2750, 5-HT3 serotonin receptor antagonist, NK-1 receptor antagonist - Advanced Solid Tumors, Malignant Neoplasm	Phase 1 / Phase 2	Not yet recruiting	Merck Sharp & Dohme LLC	300	2026-11-16	2026-10-15
Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer Isopropyl Alcohol, Placebo, Questionnaire Administration - Malignant Neoplasm	Phase 2	Not yet recruiting	M.D. Anderson Cancer Center	112	2026-11-05	2026-05-27
Pragmatic Interventions to Advance Cancer Survivor Outcomes Clinical Care decisions - Cancer, Malignant Neoplasm		Not yet recruiting	University of Texas Southwestern Medical Center	10000	2026-11-01	2026-10-21
A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01) Belzutifan - Malignant Neoplasm	Phase 2	Recruiting	Merck Sharp & Dohme LLC	15	2026-10-13	2026-10-30
A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) MK-2010, Sacituzumab tirumotecan, Histamine H1 Receptor Antagonist - Advanced Solid Tumors, Malignant Neoplasm	Phase 2	Recruiting	Merck Sharp & Dohme LLC	200	2026-10-07	2026-10-15
Clinical Application of FAP-Targeted Radionuclide Imaging in the Diagnosis and Staging of Malignant Solid Tumors Novel FAP-targeted probe - Malignant Neoplasm	Early Phase 1	Not yet recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	20	2026-07-30	2026-07-16
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) Ifinatamab Deruxtecan - Malignant Neoplasm	Phase 1 / Phase 2	Recruiting	Merck Sharp & Dohme LLC	134	2026-07-06	2026-10-30
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) Pembrolizumab - Malignant Neoplasm, Carcinoma, Merkel Cell	Phase 1 / Phase 2	Recruiting	Merck Sharp & Dohme LLC	20	2026-06-23	2026-07-13
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001) MK-4884 - Malignant Neoplasm	Phase 1	Recruiting	Merck Sharp & Dohme LLC	120	2026-06-18	2026-10-06
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm	Phase 2 / Phase 3	Recruiting	Cancer Research UK	30	2026-04-01	2026-08-17
Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors PET/CT scans - Non-Small Cell Lung Cancer, Malignant Neoplasm		Recruiting	Peking University People's Hospital	80	2026-03-18	2026-04-02
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) MK-1084, Pembrolizumab, Cetuximab - Malignant Neoplasm	Phase 2	Recruiting	Merck Sharp & Dohme LLC	140	2025-12-19	2026-09-02
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) MK-4716, Pembrolizumab, Cetuximab - Malignant Neoplasm	Phase 1	Recruiting	Merck Sharp & Dohme LLC	250	2025-12-16	2026-10-30
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. Entrectinib - Haematological Malignancy, Malignancy	Phase 2 / Phase 3	Recruiting	Cancer Research UK	30	2025-11-30	2025-11-24
Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics Immunotherapy Monitoring and Sample Collection - Malignant Neoplasm, Organ Damage		Recruiting	Hebei Medical University Fourth Hospital	2000	2025-09-15	2026-03-23
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate - Malignant Neoplasm	Phase 2	Recruiting	Merck Sharp & Dohme LLC	250	2025-08-11	2026-10-06
Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers CD-001 - Malignant Neoplasm, Head &Amp; Neck Cancer	Phase 1	Not yet recruiting	West China Hospital	9	2025-08-10	2025-08-03
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) Patritumab Deruxtecan - Malignant Neoplasm	Phase 1 / Phase 2	Recruiting	Merck Sharp & Dohme LLC	50	2025-05-26	2026-10-06
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) MK-4700, Pembrolizumab - Malignant Neoplasm	Phase 1	Completed	Merck Sharp & Dohme LLC	5	2025-04-23	2026-03-16
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) MK-3120 - Advanced Solid Tumors, Malignant Neoplasm	Phase 1 / Phase 2	Recruiting	Merck Sharp & Dohme LLC	270	2025-03-25	2026-10-28

Showing 20 of 221. Sign in to see all of them.

Narrower conditions

Neoplasms (221)  ·  Neoplasm Metastasis (11)  ·  Breast Neoplasms (9)  ·  Melanoma (9)  ·  Carcinoma, Non-Small-Cell Lung (8)  ·  Colorectal Neoplasms (8)  ·  Lung Neoplasms (7)  ·  Brain Neoplasms (6)  ·  Head and Neck Neoplasms (6)  ·  Hematologic Neoplasms (6)  ·  Lymphoma (6)  ·  Pain (6)  ·  Colonic Neoplasms (5)  ·  Lymphoproliferative Disorders (5)  ·  Multiple Myeloma (5)

Broader conditions

Neoplasms by Site (37)  ·  Pathological Conditions, Signs and Symptoms (35)  ·  Neoplasms by Histologic Type (27)  ·  Hemic and Lymphatic Diseases (24)  ·  Respiratory Tract Diseases (24)  ·  Pathologic Processes (23)  ·  Digestive System Diseases (22)  ·  Immune System Diseases (21)  ·  Neoplasms, Glandular and Epithelial (21)  ·  Urogenital Diseases (20)  ·  Neuroectodermal Tumors (19)  ·  Gastrointestinal Diseases (18)  ·  Immunoproliferative Disorders (18)  ·  Lung Diseases (18)  ·  Lymphatic Diseases (18)

Interventions

Magnetic Resonance Spectroscopy (10)  ·  Methods (8)  ·  Practice Guidelines as Topic (8)  ·  Dexamethasone (7)  ·  Early Intervention, Educational (7)  ·  Standard of Care (7)  ·  Interviews as Topic (6)  ·  Positron Emission Tomography Computed Tomography (6)  ·  pembrolizumab (5)  ·  Palonosetron (4)  ·  Cetuximab (3)  ·  Counseling (3)  ·  Cyclophosphamide (3)  ·  Educational Status (3)  ·  Gallium-68 (3)

Sponsors

M.D. Anderson Cancer Center (29)  ·  Merck Sharp & Dohme LLC (12)  ·  Wake Forest University Health Sciences (12)  ·  City of Hope Medical Center (10)  ·  National Cancer Institute (NCI) (10)  ·  University of Southern California (10)  ·  Children's Oncology Group (6)  ·  Mayo Clinic (6)  ·  OHSU Knight Cancer Institute (6)  ·  Cancer Research UK (5)  ·  Case Comprehensive Cancer Center (5)  ·  Jonsson Comprehensive Cancer Center (5)  ·  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (5)  ·  First Affiliated Hospital of Fujian Medical University (4)  ·  Roswell Park Cancer Institute (4)

Countries

United States (169)  ·  China (25)  ·  Canada (9)  ·  South Korea (8)  ·  Spain (8)  ·  United Kingdom (8)  ·  Israel (6)  ·  Taiwan (6)  ·  Chile (5)  ·  France (5)  ·  Australia (4)  ·  Brazil (4)  ·  Germany (4)  ·  Netherlands (4)  ·  Puerto Rico (4)

Top investigators

Matthew Krebs, Dr (4)  ·  Aminah Jatoi, M.D. (3)  ·  David Hui (3)  ·  Weibing Miao, MD (3)  ·  Xiaoli Lan, PhD (3)  ·  Joan E Haase (2)  ·  Patrick Williams (2)  ·  Salahadin Abdi (2)  ·  Sarina A Piha-Paul (2)  ·  Wolfgang Fendler, MD (2)  ·  Yong He, MD, PhD (2)  ·  Aaron Moberly, MD (1)  ·  Afshin Dowlati (1)  ·  Ahmed Kaseb (1)

Results publications

PMID 15240677, PMID 18276844, PMID 18974373, PMID 20157582, PMID 20837940, PMID 21239698, PMID 22323820, PMID 22394984, PMID 22658127, PMID 23160470, PMID 23217054, PMID 24001635, PMID 24668327, PMID 26094889, PMID 26438237, PMID 26586415, PMID 26688544, PMID 27226436, PMID 27282289, PMID 27411588, PMID 27435312, PMID 28397821, PMID 28837207, PMID 29319049, PMID 29634946, PMID 29802087, PMID 29924973, PMID 30304652, PMID 30573690, PMID 30946436, PMID 31044307, PMID 31630479, PMID 32153208, PMID 32414376, PMID 32771060, PMID 33289280, PMID 33388382, PMID 33452634, PMID 33609152, PMID 33640578, PMID 33929874, PMID 34241652, PMID 34556528, PMID 34717616, PMID 34926296, PMID 34950688, PMID 35199492, PMID 35363271, PMID 35657428, PMID 35810555

NIH funding

P30CA016672 (13), P30CA014089 (10), P30CA012197 (8), 2025 (5), P30CA015704 (5), U10CA095861 (4), UG1CA189823 (4), N01CM62202 (3), P30CA043703 (3), U01CA062487 (3), U01CA062491 (3), P30CA014599 (2), P30CA033572 (2), P30CA072720 (2), U01CA062505 (2)